Gilead: Too Early for Kite Credit?

Shares of Gilead Sciences have rallied since it announced the agreement to buy Kite Pharma. One team of analysts thinks about what comes next for the stock.
Source: Barrons

Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>